Results 121 to 130 of about 44,644 (146)

Druggable Targets, Clinical Trial Design and Proposed Pharmacological Management in Fibrodysplasia Ossificans Progressiva

Expert Opinion on Orphan Drugs, 2020
Robert J Pignolo, Frederick Kaplan
exaly  

Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva

New England Journal of Medicine, 1996
Michael Zasloff, Maximilian Muenke, Frederick Kaplan   +2 more
exaly  

Neofunction of ACVR1 in Fibrodysplasia Ossificans Progressiva

Proceedings of the National Academy of Sciences of the United States of America, 2015
Junya Toguchida, Makoto Ikeya, Shuichi Matsuda   +2 more
exaly  

From Mysteries to Medicines: Drug Development for Fibrodysplasia Ossificans Progressiva

Expert Opinion on Orphan Drugs, 2013
Robert J Pignolo, Frederick Kaplan, Eileen M Shore   +2 more
exaly  

Conductive Hearing Loss in Individuals With Fibrodysplasia Ossificans Progressiva

American Journal of Audiology, 1999
Frederick Kaplan, Charles E Levy, Hal B Janoff   +2 more
exaly  

Hard Targets for a Second Skeleton: Therapeutic Horizons for Fibrodysplasia Ossificans Progressiva (FOP)

Expert Opinion on Orphan Drugs, 2017
Robert J Pignolo, Frederick Kaplan, Eileen M Shore   +2 more
exaly  

Permanent Heterotopic Ossification at the Injection Site After Diphtheria-Tetanus-Pertussis Immunizations in Children Who Have Fibrodysplasia Ossificans Progressiva

Journal of Pediatrics, 1995
Michael Zasloff, David Rocke, Frederick Kaplan   +2 more
exaly  

Quality of Life of Patients With Fibrodysplasia Ossificans Progressiva

Journal of Children's Orthopaedics, 2015
Douglas Colmenares-Bonilla
exaly  

Fibrodysplasia Ossificans Progressiva

2016
openaire   +2 more sources

Insights From a Rare Genetic Disorder of Extra-Skeletal Bone Formation, Fibrodysplasia Ossificans Progressiva (FOP)

Bone, 2008
Frederick Kaplan, Eileen M Shore
exaly